Clearline Capital’s Encompass Health EHC Stock Holding History

Clearline Capital’s Portfolio EHC Stock Details EHC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-79,774	Closed	-$4.51M	–	145
2022 Q1	$4.51M	Sell	79,774 -6,626	-8%	-$346K	0.52%	46
2021 Q4	$4.49M	Buy	86,400 +81,006	+1,502%	+$4.18M	0.49%	50
2021 Q3	$322K	Sell	5,394 -15,978	-75%	-$1.01M	0.03%	132
2021 Q2	$1.33M	Buy	+21,372	New	+$1.42M	0.2%	81

Other funds holding EHC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Clearline Capital's EHC Position: Q2 2022 in Review

Clearline Capital sold out of Encompass Health (EHC) in Q2 2022, closing a stake of 79,774 shares — an estimated $4.51M sold.

Clearline Capital first reported a position in EHC in Q2 2021 and held it in 4 quarters. The position peaked at $4.51M in Q1 2022. 394 funds tracked by Wall St. Rank hold EHC as of Q2 2022.

Clearline Capital reported no remaining Encompass Health position as of Q2 2022 after selling out during the quarter.
Clearline Capital sold 79,774 Encompass Health shares in Q2 2022, an estimated $4.51M.
Clearline Capital first reported a position in Encompass Health in Q2 2021 and held it in 4 quarters.
Clearline Capital's Encompass Health position peaked at $4.51M in Q1 2022.
394 funds tracked by Wall St. Rank held Encompass Health as of Q2 2022.

Based on Clearline Capital's 13F filing for Q2 2022, filed 15 Aug 2022.